WIRE — MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix) provides a market update on its commercial and operational performance for the quarter ended June30, 2026 (Q2 2026). Q2 2026 Highlights[1] Group revenue... The post Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress appeared first on Kosmo Digital.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.